Fujifilm to invest $1.6bn and make its Hillerød facility in Denmark the largest end-to-end CDMO in Europe

By Jane Byrne

- Last updated on GMT

© Fujifilm Diosynth Biotechnologies (FDB)
© Fujifilm Diosynth Biotechnologies (FDB)

Related tags Fujifilm diosynth biotechnologies Cell culture bioreactor

Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).

Almost all of the investment will be ploughed into FDB's site in Hillerød, Denmark, which Fujifilm acquired from Biogen​ in August 2019.

Some 450 jobs will be created at the Danish campus, to add to the 1,055 employees currently on-site, said the company.

Additional bioreactors

The investment will make the Hillerød facility the largest end-to-end CDMO in Europe, reported Fujifilm, with the addition of eight 20,000L bioreactors and two downstream processing streams. That site will, thus, be able to provide a total of 20 20,000L bioreactors for drug substance production complimented by drug product and finished goods services.

Sustainable production enhancements at the Danish plant will include installation of an electric rather than a conventional boiler powered by natural gas, with FDB saying the move would, thereby, remove that site's operational dependency on fossil fuels.

In addition, FDB is investing in programs aimed at reduction of water consumption.

Texas site to benefit

A percentage of the financial outlay will also go towards the CDMO’s single-use cell culture manufacturing site in Texas, US, enabling expansion of services at that facility. The organization is planning to install its SymphonX equipment to enable cGMP MaruX continuous processing at that facility.

In MaruX, it said, the latest advancements in upstream and downstream continuous biomanufacturing have been combined to form an integrated end-to-end process that allows for a more efficient production of antibodies with consistent quality.

FDB’s SymphonX is an automated and customizable technology platform for end-to-end downstream purification developed in-house through its process development and manufacturing innovation program. The system provides the connectivity, integration and advanced automation needed to finally realize the high-productivity promise of continuous processing, said the CDMO.

A spokesperson told us that, for both FDB sites, all innovation will be online by 2026.

Growing healthcare business

In recent years, Fujifilm has announced investments​ of over US$7.1bn (€6.7bn) to grow its CDMO business unit globally.

For the year ended March 31, 2022, the group reported global revenues of approximately US$21bn, with the entire healthcare business unit segment growing into the largest operating segment of Fujifilm for the first time, in terms of both revenue and operating income.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Related suppliers

Follow us


View more